Physician profile
John E Witbeck
NPI 1972522316
$4,704.43
in general payments reported to CMS, 2019-2025
39 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $1,147 · 2021: $452 · 2022: $717 · 2023: $672 · 2024: $887 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,059.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,144.46 | 2020-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Abbvie INC. | $929.37 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $345.69 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.05 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $240.09 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Abbott Laboratories | $208.03 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Phathom Pharmaceuticals, INC. | $189.53 | 2024 | Voquezna |
| Dynavax Technologies Corporation | $125.40 | 2019-2025 | Heplisav-B |
| Gilead Sciences, INC. | $113.38 | 2019-2025 | |
| Amgen INC. | $90.18 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Pfizer INC. | $87.55 | 2019-2025 | |
| Novo Nordisk INC | $72.20 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $62.84 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $61.00 | 2019-2023 | Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $56.57 | 2020-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Witbeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.